Recommendation 2.7
➤ In people with glioblastoma, IDH-wildtype, CNS WHO grade 4
with older age, poor performance status or with concerns about
toxicity or prognosis, best supportive care alone, hypofractionated
radiation therapy alone (for MGMT promotor unmethylated tumors)
or temozolomide alone (for MGMT promotor methylated tumors) are
reasonable options. See Clinical Interpretation for further explanation.
(Weak recommendation; IC-L)
Recommendation 2.8
➤ No recommendation for or against any therapeutic strategy can be
made for treatment of recurrent glioblastoma, IDH-wildtype, CNS WHO
grade 4. (No recommendation; IC-L)
• People with recurrent glioblastoma should be referred for participation in a clinical
trial where possible. (Strong recommendation; IC-N-L).
Recommendation 2.9
➤ No recommendation for or against any therapeutic strategy can be made
for treatment of diffuse midline glioma. (No recommendation; IC-L)
• People with diffuse midline glioma should be referred for participation in a clinical
trial when possible. (Strong recommendation; IC-N-L).
